Reviva Pharmaceuticals Holdings (RVPH) EBT (2018 - 2026)

Reviva Pharmaceuticals Holdings has disclosed EBT across 9 years of filings, most recently posting -$2.4 million for Q2 2026.

• In Q2 2026, EBT rose 59.55% year-over-year to -$2.4 million; the TTM figure through Jun 2026 stood at -$13.1 million (up 51.65% YoY), while the FY2025 annual figure was -$19.9 million, up 33.33% from the prior year.
• EBT came in at -$2.4 million for Q2 2026 at Reviva Pharmaceuticals Holdings, up from -$3.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$2.4 million in Q2 2026 to a low of -$12.1 million in Q4 2022.
• Average EBT over 5 years is -$6.8 million, with a median of -$6.6 million recorded in 2023.
• Year-over-year, EBT plunged 676.11% in 2022 and surged 59.55% in 2026.
• Over 5 years, EBT stood at -$12.1 million in 2022, then climbed by 22.02% to -$9.4 million in 2023, then jumped by 33.58% to -$6.3 million in 2024, then jumped by 44.79% to -$3.5 million in 2025, then increased by 29.19% to -$2.4 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$2.4 million in Q2 2026, -$3.2 million in Q1 2026, and -$3.5 million in Q4 2025.